原发性全腺体冷冻消融治疗前列腺癌:5.6年随访的生化失败与临床复发
这项回顾性研究评估了94例2002至2012年间接受原发性全腺体冷冻消融的局限性前列腺癌患者的并发症及功能与肿瘤学结局。中位随访5.6年,5年生化失败无生存率总体为81%,临床复发无生存率总体为83%。术后6个月内未达到PSA最低值<0.2ng/ml是生化失败和临床复发的独立预测因素。
要点
- 全腺体冷冻消融后5年生化失败无生存率总体81%,临床复发无生存率83%。
- 术后6个月内PSA未降至<0.2ng/ml是复发独立预测因素。
- 90天高级别并发症率3%,无直肠瘘报告,控尿率96%。
核心结论
- 原发性全腺体冷冻消融治疗局限性前列腺癌提供可接受的中期肿瘤学结局,可作为放疗或根治性前列腺切除术的替代选择。
研究设计与样本
- 回顾性评估94例2002至2012年接受原发性全腺体冷冻消融的局限性前列腺癌连续患者,采用从随访6个月开始的界标分析进行Kaplan-Meier和多变量Cox回归。
主要发现
- 75%患者为D'Amico中危(48%)或高危(27%)前列腺癌,中位随访5.6年。
- 达到PSA最低值的中位时间为3.3个月,70例患者冷冻消融后PSA<0.2ng/ml。
- 90天高级别(Clavien IIIa级)并发症率为3%,无直肠瘘报告,控尿率和勃起功能率分别为96%和11%。
- 5年生化失败无生存率(PSA最低值+2ng/ml)总体为81%,低危89%、中危78%、高危80%(p=0.46)。
- 5年临床复发无生存率总体为83%,低危94%、中危84%、高危69%(p=0.046);5年无转移生存率为95%。
关键数值与推荐
- 术后6个月内未达到PSA最低值<0.2ng/ml是生化失败(p=0.006)和临床复发(p=0.03)的独立预测因素。
临床怎么用
- 全腺体冷冻消融可作为局限性前列腺癌的替代治疗选择,术后6个月内应监测PSA最低值以识别复发高风险患者。
局限性
- 主要局限性为回顾性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively evaluated complications and functional and oncologic outcomes of 94 consecutive men who underwent primary whole-gland cryoablation for localized prostate cancer (PCa) from 2002 to 2012. Kaplan-Meier and multivariable Cox regression analyses were performed using a landmark starting at 6 mo of follow-up. In total, 75% patients had D'Amico intermediate- (48%) or high- (27%) risk PCa. Median follow-up was 5.6 yr. Median time to prostate-specific antigen (PSA) nadir was 3.3 mo, and 70 patients reached PSA <0.2ng/ml postcryoablation. The 90-d high-grade (Clavien Grade IIIa) complication rate was 3%, with no rectal fistulas reported. Continence and potency rates were 96% and 11%, respectively. The 5-yr biochemical failure-free survival (PSA nadir+2ng/ml) was 81% overall and 89% for low-, 78% for intermediate-, and 80% for high-risk PCa (p=0.46). The median follow-up was 5.6 and 5.1 yr for patients without biochemical failure and with biochemical failure, respectively. The 5-yr clinical recurrence-free survival was 83% overall and 94% for low-, 84% for intermediate-, and 69% for high-risk PCa (p=0.046). Failure to reach PSA nadir <0.2ng/ml within 6 mo postcryoablation was an independent predictor for biochemical failure (p=0.006) and clinical recurrence (p=0.03). The 5-yr metastases-free survival was 95%. Main limitation is retrospective evaluation. Primary whole-gland cryoablation for PCa provides acceptable medium-term oncologic outcomes and could be an alternative for radiation therapy or radical prostatectomy. PATIENT SUMMARY: Cryoablation is a safe, minimally-invasive procedure that uses cold temperatures delivered via probes through the skin to kill prostate cancer (PCa) cells. Whole-gland cryoablation may offer an alternative treatment option to surgery and radiotherapy. We found that patients had good cancer outcomes 5 yr after whole-gland cryoablation, and those with a prostate-specific antigen value ≥0.2ng/ml within 6 mo after treatment were more likely to have PCa recurrence.
引用
- Oishi M, Gill IS, Ashrafi AN, et al. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Eur Urol. 2018. PMID: 30274702. doi:10.1016/j.eururo.2018.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。